Covered recipient · General Payments record
ERIC LAWITZ
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$164,148.34
155 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,275.00 | 15 |
| Consulting Fee | $53,320.87 | 14 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $21,000.00 | 6 |
| Travel and Lodging | $19,785.63 | 58 |
| Food and Beverage | $2,761.24 | 59 |
| Honoraria | $1,000.00 | 2 |
| Education | $5.60 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie, Inc. | $64,516.48 | 58 |
| Gilead Sciences, Inc. | $28,246.75 | 42 |
| Intercept Pharmaceuticals, Inc. | $23,384.52 | 15 |
| F. Hoffmann-La Roche AG | $12,951.78 | 4 |
| Boehringer Ingelheim International GmbH | $8,311.95 | 7 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,790.05 | 2 |
| Siemens Medical Solutions USA, Inc. | $7,176.59 | 7 |
| E.R. Squibb & Sons, L.L.C. | $5,321.24 | 6 |
| Dova Pharmaceuticals | $4,217.93 | 5 |
| Novo Nordisk AS | $1,392.28 | 5 |
| Shionogi Inc | $755.60 | 2 |
| Merck Sharp & Dohme Corporation | $63.51 | 1 |
| PFIZER INC. | $19.66 | 1 |
Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ERIC LAWITZ
NPI 1578661716 · CMS profile ID 207873
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
SAN ANTONIO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1578661716?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ERIC LAWITZ, NPI 1578661716, CMS profile ID 207873. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578661716?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ERIC LAWITZ, NPI 1578661716, CMS profile ID 207873. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578661716?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ERIC LAWITZ, NPI 1578661716, CMS profile ID 207873, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1578661716?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
155 matching records · $164,148.34 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 155.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie, Inc. | $451.02 | 04/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248795 | CMS |
| AbbVie, Inc. | $64.31 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248799 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,777.50 | 04/26/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749863421 | CMS |
| Dova Pharmaceuticals | $3,750.00 | 04/23/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705226845 | CMS |
| Dova Pharmaceuticals | $258.60 | 04/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705228091 | CMS |
| Dova Pharmaceuticals | $119.63 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705229481 | CMS |
| Dova Pharmaceuticals | $75.69 | 04/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705230731 | CMS |
| Gilead Sciences, Inc. | $670.00 | 04/22/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679260479 | CMS |
| Gilead Sciences, Inc. | $15.69 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681549097 | CMS |
| Intercept Pharmaceuticals, Inc. | $500.00 | 04/17/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702089047 | CMS |
| PFIZER INC. | $19.66 | 04/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672124530 | CMS |
| Gilead Sciences, Inc. | $83.53 | 04/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681549095 | CMS |
| Dova Pharmaceuticals | $14.01 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705236849 | CMS |
| Merck Sharp & Dohme Corporation | $63.51 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695887497 | CMS |
| E.R. Squibb & Sons, L.L.C. | $48.72 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651280081 | CMS |
| E.R. Squibb & Sons, L.L.C. | $27.25 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651280083 | CMS |
| AbbVie, Inc. | $1,250.00 | 03/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248781 | CMS |
| Siemens Medical Solutions USA, Inc. | $50.00 | 03/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 631943681 | CMS |
| Gilead Sciences, Inc. | $13.41 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681549093 | CMS |
| Intercept Pharmaceuticals, Inc. | $124.99 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702089039 | CMS |
| Intercept Pharmaceuticals, Inc. | $3,400.00 | 03/19/2019 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702089043 | CMS |
| Siemens Medical Solutions USA, Inc. | $6,250.00 | 03/19/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 631943675 | CMS |
| Siemens Medical Solutions USA, Inc. | $44.87 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 631943685 | CMS |
| Siemens Medical Solutions USA, Inc. | $317.86 | 02/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 631943701 | CMS |
| Gilead Sciences, Inc. | $14.38 | 02/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679347587 | CMS |
| Gilead Sciences, Inc. | $50.00 | 02/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679347589 | CMS |
| Gilead Sciences, Inc. | $8.56 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681549091 | CMS |
| Gilead Sciences, Inc. | $13.50 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681549089 | CMS |
| Gilead Sciences, Inc. | $3,720.00 | 02/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679312333 | CMS |
| Gilead Sciences, Inc. | $250.00 | 02/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679347575 | CMS |
| Gilead Sciences, Inc. | $354.00 | 02/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679347583 | CMS |
| Gilead Sciences, Inc. | $582.98 | 02/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679347585 | CMS |
| Gilead Sciences, Inc. | $43.70 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681549083 | CMS |
| Gilead Sciences, Inc. | $49.98 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681549085 | CMS |
| Gilead Sciences, Inc. | $119.98 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681549087 | CMS |
| Siemens Medical Solutions USA, Inc. | $330.26 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 631943689 | CMS |
| Siemens Medical Solutions USA, Inc. | $9.00 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 631943692 | CMS |
| AbbVie, Inc. | $67.98 | 02/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248759 | CMS |
| Intercept Pharmaceuticals, Inc. | $500.00 | 02/05/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702089033 | CMS |
| AbbVie, Inc. | $4,375.00 | 02/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248745 | CMS |
| AbbVie, Inc. | $4,375.00 | 02/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248753 | CMS |
| AbbVie, Inc. | $4,375.00 | 02/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248761 | CMS |
| AbbVie, Inc. | $404.00 | 01/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248739 | CMS |
| AbbVie, Inc. | $17.63 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248763 | CMS |
| AbbVie, Inc. | $150.70 | 01/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248765 | CMS |
| AbbVie, Inc. | $17.32 | 01/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248741 | CMS |
| AbbVie, Inc. | $108.41 | 01/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248743 | CMS |
| AbbVie, Inc. | $297.29 | 01/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248749 | CMS |
| AbbVie, Inc. | $382.23 | 01/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248757 | CMS |
| AbbVie, Inc. | $127.34 | 01/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648248747 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $306.91 | 7 |
| PY2025 | Principal investigator | $11,657,092.67 | 1,309 |
| PY2024 | Recipient | $5,977.17 | 18 |
| PY2024 | Principal investigator | $8,383,016.22 | 257 |
| PY2023 | Recipient | $29,294.75 | 36 |
| PY2023 | Principal investigator | $9,948,237.96 | 366 |
| PY2022 | Recipient | $412.01 | 3 |
| PY2022 | Principal investigator | $6,740,494.10 | 397 |
| PY2021 | Recipient | $249.50 | 1 |
| PY2021 | Principal investigator | $5,223,910.82 | 847 |
| PY2020 | Recipient | $10,691.56 | 1 |
| PY2020 | Principal investigator | $8,262,804.27 | 280 |
| PY2019 | Recipient | $1,913.39 | 3 |
| PY2019 | Principal investigator | $8,493,525.14 | 307 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
1,316 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 12/31/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783133 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $75.00 | 12/31/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $75.00 | 12/31/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783137 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $492.00 | 12/31/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783139 |
| Principal investigator 1 | Exelixis Inc. | $43,266.90 | 12/30/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379584 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $6,686.25 | 12/29/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783037 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,410.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,410.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783049 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783077 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783083 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 12/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $850.00 | 12/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782619 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782621 |
| Principal investigator 1 | Genentech, Inc. | $26,114.00 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572652 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $29,666.25 | 12/19/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546757 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118264 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118268 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $5,502.60 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118272 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,151.95 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118275 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118279 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118284 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,151.95 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118286 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $4,538.70 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118290 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $5,502.60 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118295 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118299 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,853.95 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118305 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $3,342.60 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118310 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $4,538.70 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118314 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,056.10 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118318 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,853.95 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118323 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,056.10 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118329 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,806.70 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118333 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $3,342.60 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118336 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,806.70 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118341 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $3,342.60 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118344 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,968.70 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118348 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,968.70 | 12/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118352 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 12/18/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $158.35 | 12/18/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $186.56 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $252.20 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782737 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $156.32 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782739 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.76 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $766.50 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782765 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $234.00 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783145 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $283.00 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) | No dispute reported | 06/30/2026 | 1220783149 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $466.40 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999037 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $244.28 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999039 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.48 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999041 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $222.72 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999043 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3.36 | 12/17/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999045 |
| Principal investigator 1 | Eli Lilly and Company | $915.38 | 12/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP INC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187874697 |
| Principal investigator 1 | Eli Lilly and Company | $1,395.66 | 12/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP INC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187874997 |
| Principal investigator 1 | Genentech, Inc. | $6,453.00 | 12/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572648 |
| Principal investigator 1 | Genentech, Inc. | $218.57 | 12/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572894 |
| Principal investigator 1 | Genentech, Inc. | $8,505.00 | 12/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572899 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $850.00 | 12/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV | No dispute reported | 06/30/2026 | 1192163087 |
| Principal investigator 1 | Ipsen Pharma SAS | $257.40 | 12/17/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306831 |
| Principal investigator 1 | Eli Lilly and Company | $313.03 | 12/16/2025 | Non-covered Recipient Entity THE TEXAS LIVER INSTITUTE | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 (SOLBINSIRAN) IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA | No dispute reported | 06/30/2026 | 1187891904 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $62,100.00 | 12/16/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.30 | 12/12/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781864 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 12/12/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 12/12/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781872 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $84,729.39 | 12/11/2025 | Non-covered Recipient Entity TEXAS LIVER INSTITUTE | A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS | No dispute reported | 06/30/2026 | 1235976889 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $4,108.52 | 12/11/2025 | Non-covered Recipient Entity TEXAS LIVER INSTITUTE | A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS | No dispute reported | 06/30/2026 | 1235976892 |
| Principal investigator 1 | Genentech, Inc. | $296.00 | 12/10/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572661 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,684.50 | 12/10/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV | No dispute reported | 06/30/2026 | 1192166436 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 12/10/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253794 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 12/10/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223289522 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $9,644.68 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171134 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $11,569.50 | 12/04/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546753 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,013.70 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184269121 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $150.00 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118158 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $348.30 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118161 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $500.00 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118165 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $500.00 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118169 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $348.30 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118172 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $5,502.60 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118177 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $150.00 | 12/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253118180 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 12/03/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781866 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 12/03/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781870 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 12/03/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783035 |
| Principal investigator 1 | Genentech, Inc. | $4,608.00 | 12/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572656 |
| Principal investigator 1 | Genentech, Inc. | $41.58 | 12/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572665 |
| Principal investigator 1 | Exelixis Inc. | $1,650.00 | 12/02/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379578 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,610.25 | 12/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572755 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $73.93 | 12/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572764 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,053.50 | 12/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV | No dispute reported | 06/30/2026 | 1192110119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,709.80 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781836 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781838 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781840 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.45 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781842 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,147.55 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781844 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.45 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781846 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781848 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781850 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781854 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781856 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781858 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 11/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781860 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,150.50 | 11/27/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253125 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $55,552.50 | 11/25/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546741 |
| Principal investigator 1 | Genentech, Inc. | $1,875.00 | 11/24/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572882 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782993 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783013 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783017 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783025 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783031 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 11/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220783033 |
| Principal investigator 1 | Genentech, Inc. | $76.02 | 11/21/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572853 |
| Principal investigator 1 | Genentech, Inc. | $9,609.00 | 11/21/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572857 |
| Principal investigator 1 | Genentech, Inc. | $77,281.00 | 11/21/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572861 |
| Principal investigator 1 | Genentech, Inc. | $214.42 | 11/21/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572866 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,673.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546673 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $439.43 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546675 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $573.75 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546677 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $95.76 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546679 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $891.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546681 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $300.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546683 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $891.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546685 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $891.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546687 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $750.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546689 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $891.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546691 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,814.49 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546693 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $300.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546695 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $142.57 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546697 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $750.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546699 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $750.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546701 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,673.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546731 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $300.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546733 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $891.00 | 11/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $929.20 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781892 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $766.50 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.00 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782729 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $600.00 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,700.00 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $810.00 | 11/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782979 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $105.00 | 11/19/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818685 |
| Principal investigator 1 | Genentech, Inc. | $35.87 | 11/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572845 |
| Principal investigator 1 | Genentech, Inc. | $60,446.00 | 11/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572870 |
| Principal investigator 1 | Genentech, Inc. | $42,483.00 | 11/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572874 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $386.10 | 11/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192163111 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $675.00 | 11/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223288543 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $72,433.00 | 11/18/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818683 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $21,082.94 | 11/18/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192166444 |
| Principal investigator 1 | Genentech, Inc. | $5,304.00 | 11/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572890 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $3,750.00 | 11/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | No dispute reported | 06/30/2026 | 1248171136 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,494.50 | 11/14/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546713 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,386.00 | 11/14/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306999 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,740.50 | 11/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252637 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $750.00 | 11/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252645 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,039.55 | 11/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184261301 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $59.64 | 11/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223288355 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $1,350.00 | 11/13/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.30 | 11/12/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781862 |
| Principal investigator 1 | Genentech, Inc. | $76.02 | 11/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572849 |
| Principal investigator 1 | Genentech, Inc. | $4,171.50 | 11/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572878 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $131.95 | 11/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV | No dispute reported | 06/30/2026 | 1192166440 |
| Principal investigator 1 | Genentech, Inc. | $29,295.00 | 11/10/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572887 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,996.31 | 11/07/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192166804 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $58,792.50 | 11/07/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546705 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,111.60 | 11/07/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258887 |
| Principal investigator 1 | Ipsen Pharma SAS | $514.80 | 11/05/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306827 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,233.60 | 11/05/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306829 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $600.00 | 11/05/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093770 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $15,925.80 | 11/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572746 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $18,485.06 | 11/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192110126 |
| Principal investigator 1 | H. Lundbeck A S | $3,000.00 | 11/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | Hepatic Impairment Study | No dispute reported | 06/30/2026 | 1251776523 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $3,908.25 | 11/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093768 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,683.88 | 11/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223287885 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $150.00 | 10/30/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117931 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $500.00 | 10/30/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117935 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $150.00 | 10/30/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117940 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $150.00 | 10/30/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117943 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $500.00 | 10/30/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117948 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $500.00 | 10/30/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117952 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $48.72 | 10/29/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818679 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $367,204.00 | 10/28/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818677 |
| Principal investigator 1 | Gilead Sciences, Inc. | $8,638.23 | 10/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION, INC. | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781874 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781876 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781878 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $131.10 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781880 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.07 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781882 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.07 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781884 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.07 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781886 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.07 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781888 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.50 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781890 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.00 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $105.00 | 10/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783131 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $48.72 | 10/27/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818675 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $11,005.20 | 10/27/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117927 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,203.00 | 10/23/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818673 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $675.00 | 10/23/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,410.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,410.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,410.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,410.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,410.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 10/22/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782973 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,684.50 | 10/22/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV | No dispute reported | 06/30/2026 | 1192166800 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,908.71 | 10/22/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223287201 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,957.50 | 10/22/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223287235 |
| Principal investigator 1 | Genentech, Inc. | $40,335.00 | 10/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572832 |
| Principal investigator 1 | Genentech, Inc. | $3,656.00 | 10/17/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | CPET | No dispute reported | 06/30/2026 | 1211603528 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $810.00 | 10/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223287125 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,233.40 | 10/16/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184250493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 10/15/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/15/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,700.00 | 10/15/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782609 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 10/15/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782611 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 10/15/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782613 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $900.00 | 10/15/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,000.00 | 10/15/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782617 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,093.25 | 10/14/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818671 |
| Principal investigator 1 | Exelixis Inc. | $38,138.25 | 10/14/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379572 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 10/08/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781832 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/06/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $900.00 | 10/06/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782795 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.37 | 10/06/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818668 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $602.99 | 10/03/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818681 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,543.35 | 10/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184244539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $253.04 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $850.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782807 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782819 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782821 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782829 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782831 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,778.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,516.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,841.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,443.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 10/02/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782953 |
| Principal investigator 2 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,000.00 | 10/01/2025 | Non-covered Recipient Entity Centricity Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220812222 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $63.51 | 10/01/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818664 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,743.15 | 10/01/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818666 |
| Principal investigator 1 | Genentech, Inc. | $17,200.00 | 10/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572836 |
| Principal investigator 1 | Genentech, Inc. | $13,824.00 | 10/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib | No dispute reported | 06/30/2026 | 1211572841 |
| Principal investigator 1 | H. Lundbeck A S | $25,100.00 | 10/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | Hepatic Impairment Study | No dispute reported | 06/30/2026 | 1251775125 |
| Principal investigator 1 | Exelixis Inc. | $10,359.87 | 09/30/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379574 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781800 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781804 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781806 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781810 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781812 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781814 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,886.30 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,147.55 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781826 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 09/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781830 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,477.77 | 09/25/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192170018 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.60 | 09/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.88 | 09/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 09/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $549.63 | 09/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.33 | 09/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.56 | 09/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783129 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11.66 | 09/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999033 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2.32 | 09/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999035 |
| Principal investigator 1 | Genentech, Inc. | $71.74 | 09/24/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572794 |
| Principal investigator 1 | Genentech, Inc. | $81,625.00 | 09/24/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572798 |
| Principal investigator 1 | Genentech, Inc. | $16,303.00 | 09/24/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572807 |
| Principal investigator 1 | Genentech, Inc. | $153.14 | 09/24/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572812 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $950.00 | 09/23/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546635 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,543.00 | 09/23/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546637 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $3,908.25 | 09/22/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093673 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,823.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,700.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $950.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,700.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,000.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,536.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,308.00 | 09/19/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220782791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,337.90 | 09/18/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184240824 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $22,300.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP, 2-PART STUDY TO EV | No dispute reported | 06/30/2026 | 1192166448 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,152.38 | 09/15/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192170031 |
| Principal investigator 1 | Ipsen Pharma SAS | $380.00 | 09/12/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306997 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,000.10 | 09/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184236522 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $506.25 | 09/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192110109 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $29,481.88 | 09/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192163092 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,518.75 | 09/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192166790 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $33,439.85 | 09/10/2025 | Non-covered Recipient Entity American Research Corporation | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12,636.00 | 09/08/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783169 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782507 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782587 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782589 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782593 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,215.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,474.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782601 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $80.00 | 09/05/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782603 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,065.40 | 09/05/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249794 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $29,302.15 | 09/05/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223285161 |
| Principal investigator 1 | Genentech, Inc. | $36,400.00 | 09/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572828 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,358.26 | 09/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192110102 |
| Principal investigator 1 | Exelixis Inc. | $1,009.37 | 09/02/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379590 |
| Principal investigator 1 | Genentech, Inc. | $9,830.00 | 09/02/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Ph1c proof of activity study of GDC-6988 in patients with COPD and NCFB | No dispute reported | 06/30/2026 | 1211601454 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $337.50 | 09/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192166432 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $654.75 | 09/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223284749 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.30 | 09/01/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781822 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,886.30 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,886.30 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781712 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,886.30 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781716 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781724 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781726 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781728 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,103.30 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,241.05 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,147.55 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,241.05 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,103.30 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,147.55 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781754 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,709.80 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781758 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,709.80 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781764 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,709.80 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781766 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781768 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 08/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781770 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $29,390.83 | 08/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093619 |
| Principal investigator 1 | Gilead Sciences, Inc. | $21,868.37 | 08/27/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION, INC. | An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) | No dispute reported | 06/30/2026 | 1229203000 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $305.35 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.85 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.20 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783117 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $513.04 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999023 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $244.28 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999025 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.48 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999027 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $232.00 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999029 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3.36 | 08/26/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999031 |
| Principal investigator 1 | Exelixis Inc. | $1,502.92 | 08/26/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379576 |
| Principal investigator 1 | Exelixis Inc. | $35.87 | 08/26/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379580 |
| Principal investigator 1 | Gilead Sciences, Inc. | $600.00 | 08/26/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION, INC. | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203766 |
| Principal investigator 1 | Genentech, Inc. | $8,215.69 | 08/20/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572802 |
| Principal investigator 1 | Eli Lilly and Company | $159,153.56 | 08/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP INC | A PHASE 1, MULTICENTER, PARALLEL-DESIGN, SINGLE-DOSE, OPEN-LABEL STUDY OF LEPODISIRAN IN PARTICIPANTS WITH NORMAL HEPATIC FUNCTION AND PARTICIPANTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1187874457 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,041.50 | 08/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248791 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $425.25 | 08/18/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192163107 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $425.25 | 08/18/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192166428 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $2,025.00 | 08/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171128 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,987.25 | 08/14/2025 | Non-covered Recipient Entity American Research Corporation | A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity | No dispute reported | 06/30/2026 | 1184306825 |
| Principal investigator 1 | ABBVIE INC. | $2,430.00 | 08/13/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine | No dispute reported | 06/30/2026 | 1202504511 |
| Principal investigator 1 | ABBVIE INC. | $15,902.91 | 08/13/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine | No dispute reported | 06/30/2026 | 1202504527 |
| Principal investigator 1 | ABBVIE INC. | $4,462.20 | 08/13/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine | No dispute reported | 06/30/2026 | 1202504529 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,500.00 | 08/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572720 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,000.00 | 08/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572733 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,792.52 | 08/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192166823 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $11,724.75 | 08/08/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093595 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $47.04 | 08/08/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $850.00 | 08/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,020.00 | 08/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782483 |
| Principal investigator 1 | Ipsen Pharma SAS | $16,659.00 | 08/07/2025 | Non-covered Recipient Entity American Research Corporation | A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity | No dispute reported | 06/30/2026 | 1184306823 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,374.20 | 08/06/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306819 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,464.00 | 08/06/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306821 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,806.70 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117758 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117762 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,806.70 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117766 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,853.95 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117770 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,056.10 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117774 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $3,342.60 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117778 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $5,502.60 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117783 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,853.95 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117787 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,968.70 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117792 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117797 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $4,538.70 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117800 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $5,502.60 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117805 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117811 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,151.95 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117815 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $4,538.70 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117819 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,968.70 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117823 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,056.10 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117827 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,151.95 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117830 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $3,342.60 | 08/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117834 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $41,553.20 | 08/01/2025 | Non-covered Recipient Entity American Research Corporation | Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis | No dispute reported | 06/30/2026 | 1220818691 |
| Principal investigator 1 | Genentech, Inc. | $1,123.16 | 08/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572823 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $650.70 | 08/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223283571 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $202.50 | 08/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223283573 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,136.80 | 08/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223283575 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $9,497.25 | 07/31/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546593 |
| Principal investigator 1 | Exelixis Inc. | $465.30 | 07/30/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379582 |
| Principal investigator 1 | Exelixis Inc. | $1,066.82 | 07/30/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,646.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781772 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $163.24 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781774 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $459.54 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781776 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $657.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781778 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $916.05 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781780 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $437.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781782 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.70 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781784 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781786 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.35 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $117.50 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $433.87 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782367 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $87.67 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782369 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $38.87 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782371 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,065.50 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,032.75 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782455 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $850.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782457 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $600.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $336.08 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $313.07 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $293.62 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.75 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $138.22 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $118.86 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $95.76 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.88 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.87 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.24 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782707 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.24 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782749 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783097 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $305.35 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.85 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.20 | 07/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220783105 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $18,358.63 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093585 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,056.10 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117281 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,151.95 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117284 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,806.70 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117288 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,968.70 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117292 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,853.95 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117296 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $3,342.60 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117301 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $5,502.60 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117303 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,056.10 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117307 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,151.95 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117312 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $4,538.70 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117317 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,806.70 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117320 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,968.70 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117324 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $6,853.95 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117328 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $3,342.60 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117332 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $654.75 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117336 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $5,502.60 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117340 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $4,538.70 | 07/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117345 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,935.75 | 07/25/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223283184 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,188.78 | 07/25/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223283202 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.14 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.86 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.00 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782689 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782691 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.00 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782693 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.00 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.25 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782699 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.31 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782701 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $190.50 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.71 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220782705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $170.80 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.25 | 07/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220782743 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,000.00 | 07/22/2025 | Non-covered Recipient Entity American Research Corporation | Pharmacokinetics, safety and tolerability of BI 1584862 in male and female participants with different degrees of hepatic impairment (Child-Pugh class A, B, and C) compared with matched male and female participants with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220818662 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,747.25 | 07/22/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546591 |
| Principal investigator 1 | Gilead Sciences, Inc. | $992.40 | 07/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION, INC. | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203776 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $17,043.75 | 07/17/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546589 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,337.90 | 07/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217020 |
| Principal investigator 1 | Genentech, Inc. | $1,701.00 | 07/16/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572816 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,936.25 | 07/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572724 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,569.15 | 07/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192110130 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $20,221.30 | 07/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192163115 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,261.15 | 07/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192166794 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $67,142.25 | 07/10/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546587 |
| Principal investigator 1 | Exelixis Inc. | $1,883.25 | 07/08/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379588 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782373 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782375 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782377 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782379 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782381 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782383 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782385 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782387 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782389 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782391 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782393 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782395 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782397 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782399 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782401 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782403 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782407 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782411 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782421 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782423 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782429 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782433 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782443 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782447 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 07/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782451 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,674.00 | 07/07/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572716 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $654.75 | 07/07/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223282386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 07/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $207.90 | 07/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781706 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $9,497.25 | 07/04/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546585 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,835.60 | 07/04/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306815 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,324.10 | 07/04/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306817 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,006.00 | 07/04/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,337.90 | 07/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184212741 |
| Principal investigator 1 | Genentech, Inc. | $5,029.52 | 07/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572819 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,875.00 | 07/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572729 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $12,514.50 | 07/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572737 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,626.35 | 07/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 06/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781584 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 06/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781626 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 06/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781632 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $369.30 | 06/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781650 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.30 | 06/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781624 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $43,783.74 | 06/25/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP | A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SA | No dispute reported | 06/30/2026 | 1192170036 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781542 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,103.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781544 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781546 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781548 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781550 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781552 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781554 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,241.05 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781558 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,147.55 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781560 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781562 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781564 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,241.05 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781572 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,103.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781574 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781576 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,886.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781578 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781580 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,797.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781582 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,241.05 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,886.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781588 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,709.80 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781590 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781594 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781596 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781598 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,147.55 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781602 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781604 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,241.05 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,241.05 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781612 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781614 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781616 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,886.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781618 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,241.05 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781620 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781622 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781628 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,782.70 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781630 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781634 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781636 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781640 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,147.55 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781642 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,709.80 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781644 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,103.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781646 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,103.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781648 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781652 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,103.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781654 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,886.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781658 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781660 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,501.20 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,709.80 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,103.30 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781670 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,709.80 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,147.55 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,602.45 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781676 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $711.26 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999013 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $366.42 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999015 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2.22 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999017 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $336.40 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999019 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5.04 | 06/24/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Open label, single dose, parallel-group study to evaluate the PK and the safety and tolerability of single oral doses of BI 1291583 in trial participants with mild, moderate and severe hepatic impairment as compared to matched, hepatically healthy trial participants | No dispute reported | 06/30/2026 | 1220999021 |
| Principal investigator 1 | Exelixis Inc. | $20,700.00 | 06/24/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1222379570 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,931.70 | 06/24/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546579 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,771.50 | 06/24/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546581 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,755.00 | 06/23/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572697 |
| Principal investigator 1 | Genentech, Inc. | $107,499.00 | 06/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572775 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,743.35 | 06/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184209131 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $29,295.00 | 06/16/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572705 |
| Principal investigator 1 | Genentech, Inc. | $16,231.52 | 06/13/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572783 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,037.39 | 06/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192166812 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $25,393.50 | 06/12/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546569 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,561.80 | 06/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2389 CAMPOLINA | No dispute reported | 06/30/2026 | 1185547143 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $44,049.28 | 06/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004 | No dispute reported | 06/30/2026 | 1185547151 |
| Principal investigator 1 | Genentech, Inc. | $333.00 | 06/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,268.00 | 06/09/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783167 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $272.61 | 06/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572673 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,059.75 | 06/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572682 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,171.50 | 06/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572701 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $105,927.75 | 06/05/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,337.90 | 06/05/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184204141 |
| Principal investigator 1 | ABBVIE INC. | $83,982.60 | 06/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine | No dispute reported | 06/30/2026 | 1202490135 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $42,705.90 | 06/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA | No dispute reported | 06/30/2026 | 1185547155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782295 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782299 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782301 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782305 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782309 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782313 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782315 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782317 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782319 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782321 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782323 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782325 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782327 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782329 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782331 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782333 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782335 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782337 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782339 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782341 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782343 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782345 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782347 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782349 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782351 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782353 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782355 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782357 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782359 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782361 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782363 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 06/04/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782365 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,859.40 | 06/04/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306813 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $26,067.83 | 06/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223280696 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $10,000.00 | 06/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117232 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $2,000.00 | 06/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117235 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $5,000.00 | 06/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117238 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $3,700.00 | 06/04/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117242 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $118.86 | 06/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572669 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 06/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572678 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 06/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572684 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $10,000.00 | 06/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572688 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $218,726.25 | 06/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572693 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,700.00 | 06/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF HEPATIC IMPAIRMENT OF SUBJECTS GIVEN CT388 | No dispute reported | 06/30/2026 | 1211572711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $138.60 | 05/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781678 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 05/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248244682 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,161.50 | 05/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781690 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 05/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 05/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781694 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 05/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $87.40 | 05/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781698 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.70 | 05/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781700 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.00 | 05/27/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781702 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,465.85 | 05/27/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546559 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $61,539.75 | 05/27/2025 | Non-covered Recipient Entity American Research Corporation | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose | No dispute reported | 06/30/2026 | 1176546561 |
| Principal investigator 1 | Ipsen Pharma SAS | $6,544.00 | 05/23/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306993 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $14,826.98 | 05/22/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,377.45 | 05/22/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184197553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781973 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781993 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782013 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782017 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782025 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782031 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782033 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782035 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782037 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782049 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,009.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782077 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782083 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782097 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782105 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782117 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782131 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782133 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782137 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782145 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782149 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782151 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782161 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782165 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782169 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782177 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782179 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782183 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782185 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782187 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782189 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782191 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782193 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782201 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782211 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782213 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782217 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782219 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782225 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782231 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782235 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782243 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782245 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782249 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782255 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782257 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782267 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,002.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,213.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782277 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,639.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782281 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,085.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,894.75 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782287 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,581.25 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,401.00 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,442.50 | 05/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220782293 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $23,874.73 | 05/21/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093397 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,743.35 | 05/15/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184194607 |
| Principal investigator 1 | Genentech, Inc. | $4,878.75 | 05/14/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572779 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $555.00 | 05/14/2025 | Non-covered Recipient Entity American Research Corporation | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167449 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $18,259.33 | 05/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192163083 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $3,908.25 | 05/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093385 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $96.60 | 05/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093387 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,950.80 | 05/08/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546551 |
| Principal investigator 1 | Genentech, Inc. | $2,451.70 | 05/07/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572791 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,233.60 | 05/07/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306811 |
| Principal investigator 1 | Gilead Sciences, Inc. | $6,274.57 | 05/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION, INC. | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203758 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $742.50 | 05/02/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546549 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,231.90 | 05/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223278794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.60 | 04/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781530 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 04/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781532 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 04/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781534 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 04/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781536 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,186.35 | 04/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781538 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $838.50 | 04/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781540 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,779.10 | 04/28/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546541 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,996.22 | 04/28/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 04/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781680 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 04/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781682 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $427.49 | 04/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781684 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $174.80 | 04/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781686 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.50 | 04/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781688 |
| Principal investigator 1 | Eli Lilly and Company | $1,810.12 | 04/23/2025 | Non-covered Recipient Entity THE TEXAS LIVER INSTITUTE | A PHASE 1, MULTICENTER, PARALLEL-DESIGN, SINGLE-DOSE, OPEN-LABEL STUDY OF LEPODISIRAN IN PARTICIPANTS WITH NORMAL HEPATIC FUNCTION AND PARTICIPANTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1187891104 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $10,710.55 | 04/23/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546537 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,219.72 | 04/23/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,337.90 | 04/23/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184189153 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $365.52 | 04/21/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | No dispute reported | 06/30/2026 | 1249093341 |
| Principal investigator 1 | Amgen Inc. | $1,622,855.23 | 04/16/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | An Open-Label Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants with Varying Degrees of Hepatic Impairment | No dispute reported | 06/30/2026 | 1246639107 |
| Principal investigator 1 | AstraZeneca UK Limited | $153,975.12 | 04/16/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004 | No dispute reported | 06/30/2026 | 1185547141 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,941.35 | 04/15/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,337.90 | 04/15/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184183462 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $425.25 | 04/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192163098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.24 | 04/09/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $125.58 | 04/09/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $222.06 | 04/09/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $850.00 | 04/09/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781925 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,129.73 | 04/08/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192166819 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $535.45 | 04/08/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546531 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,326.55 | 04/08/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781894 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.02 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781896 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $118.86 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781898 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $118.86 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781900 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $125.16 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781902 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,700.00 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $155.99 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,700.00 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,150.00 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $950.00 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,000.00 | 04/07/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety and tolerability of zongertinib following oral administration in male and female participants of non-childbearing potential with different degrees of hepatic impairment (Child-Pugh classification A and B) compared with matched male and female participants of non-childbearing potential with normal hepatic function (an open-label, non-randomised, single-dose, parallel, individual-matched design trial) | No dispute reported | 06/30/2026 | 1220781917 |
| Principal investigator 1 | X4 Pharmaceuticals, Inc. | $499.20 | 04/02/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | No dispute reported | 06/30/2026 | 1253117157 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,070.90 | 04/01/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546521 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $9,405.95 | 04/01/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546523 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $738.65 | 04/01/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,714.05 | 04/01/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184180948 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,000.00 | 03/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781480 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.40 | 03/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 03/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781484 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 03/28/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781486 |
| Principal investigator 1 | Genentech, Inc. | $8,006.00 | 03/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572768 |
| Principal investigator 1 | Genentech, Inc. | $16,500.00 | 03/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION INC | CPET | No dispute reported | 06/30/2026 | 1211572771 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,351.00 | 03/27/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241414 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $525.00 | 03/27/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241417 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $525.00 | 03/26/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP | A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SA | No dispute reported | 06/30/2026 | 1192170041 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,496.27 | 03/26/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN | No dispute reported | 06/30/2026 | 1223277057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,700.00 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781470 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,800.00 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781474 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781476 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781494 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $949.00 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781498 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $549.63 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781500 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $196.65 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781502 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.70 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781504 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $126.75 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $126.75 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781508 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $126.75 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781510 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $126.75 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781512 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 03/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781514 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,460.77 | 03/25/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546515 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,192.00 | 03/25/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546517 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,965.00 | 03/21/2025 | Non-covered Recipient Entity American Research Corporation | PoCP study in cirrhosis and portal hypertension | No dispute reported | 06/30/2026 | 1220818687 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,969.60 | 03/21/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192163103 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,605.50 | 03/19/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546511 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,674.00 | 03/19/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,337.90 | 03/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184174588 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,600.00 | 03/14/2025 | Non-covered Recipient Entity American Research Corporation | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546507 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,000.00 | 03/14/2025 | Non-covered Recipient Entity American Research Corporation | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176546509 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $29,693.98 | 03/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis | No dispute reported | 06/30/2026 | 1185547139 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $742.50 | 03/11/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546503 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $931.50 | 03/11/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546505 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $425,099.91 | 03/08/2025 | Non-covered Recipient Entity TEXAS LIVER INSTITUTE AMERICAN RESEARCH CORPORATION | A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Mild or Moderate Hepatic Impairment and in Matched Healthy Subjects | No dispute reported | 06/30/2026 | 1214124362 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,766.00 | 03/07/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306991 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $29,262.33 | 03/05/2025 | Non-covered Recipient Entity American Research Corporation | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167776 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,766.90 | 03/05/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306807 |
| Principal investigator 1 | Ipsen Pharma SAS | $514.80 | 03/05/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306809 |
| Principal investigator 1 | Ipsen Pharma SAS | $766.00 | 03/05/2025 | Non-covered Recipient Entity Ruane Clinical Research Group, Inc | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306989 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,460.77 | 03/04/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546499 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $7,092.70 | 03/04/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546501 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,200.00 | 03/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP | A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SA | No dispute reported | 06/30/2026 | 1192170026 |
| Recipient | Gilead Sciences, Inc. | $25.00 | 02/27/2025 | Covered Recipient Physician | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229200421 |
| Recipient | Gilead Sciences, Inc. | $25.00 | 02/27/2025 | Covered Recipient Physician | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229200430 |
| Recipient | Gilead Sciences, Inc. | $49.99 | 02/27/2025 | Covered Recipient Physician | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229200438 |
| Recipient | Gilead Sciences, Inc. | $49.99 | 02/27/2025 | Covered Recipient Physician | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229200446 |
| Recipient | Gilead Sciences, Inc. | $14.70 | 02/27/2025 | Covered Recipient Physician | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229201606 |
| Recipient | Gilead Sciences, Inc. | $14.70 | 02/27/2025 | Covered Recipient Physician | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229201615 |
| Recipient | Gilead Sciences, Inc. | $127.53 | 02/26/2025 | Covered Recipient Physician | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229200453 |
| Principal investigator 1 | Amgen Inc. | $3,464.32 | 02/25/2025 | Non-covered Recipient Entity TEXAS LIVER INSTITUTE | An Open-Label Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants with Varying Degrees of Hepatic Impairment | No dispute reported | 06/30/2026 | 1246649259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781488 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.49 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781490 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.50 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781492 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781516 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $183.21 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781518 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781520 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.05 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781522 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781524 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781526 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.21 | 02/25/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781528 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,461.12 | 02/25/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546493 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,313.25 | 02/25/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,377.45 | 02/25/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184155390 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $506.25 | 02/24/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192166454 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,066.08 | 02/24/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192166459 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,339.30 | 02/24/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223275491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 02/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783151 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,700.00 | 02/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $750.00 | 02/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 02/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 02/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,000.00 | 02/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783161 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 02/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $750.00 | 02/21/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Pharmacokinetics, safety, and tolerability of BI 685509 in subjects with severe liver impairment (Child-Pugh classification C) as compared to healthy subjects | No dispute reported | 06/30/2026 | 1220783165 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $5,878.18 | 02/20/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171126 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $931.50 | 02/20/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546491 |
| Principal investigator 1 | AstraZeneca AB | $55,200.10 | 02/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004 | No dispute reported | 06/30/2026 | 1185547147 |
| Principal investigator 1 | AstraZeneca UK Limited | $222,393.50 | 02/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA | No dispute reported | 06/30/2026 | 1185547133 |
| Principal investigator 1 | AstraZeneca UK Limited | $205,385.72 | 02/19/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2389 CAMPOLINA | No dispute reported | 06/30/2026 | 1185547145 |
| Principal investigator 1 | Ipsen Pharma SAS | $88.62 | 02/19/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306803 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,116.80 | 02/19/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306805 |
| Principal investigator 1 | Eli Lilly and Company | $488,989.00 | 02/18/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP INC | A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS | No dispute reported | 06/30/2026 | 1187876017 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,460.77 | 02/18/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546487 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,465.85 | 02/18/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,301.40 | 02/18/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154174 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $675.00 | 02/13/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171124 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,796.35 | 02/12/2025 | Non-covered Recipient Entity TEXAS LIVER INSTITUTE | A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants. | No dispute reported | 06/30/2026 | 1190303707 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,619.21 | 02/12/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis | No dispute reported | 06/30/2026 | 1223275201 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,000.00 | 02/11/2025 | Non-covered Recipient Entity American Research Corporation | Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis | No dispute reported | 06/30/2026 | 1220818689 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,219.00 | 02/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184152946 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,600.00 | 02/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223275021 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 02/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223275023 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 02/11/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223275025 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,150.50 | 02/10/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239638 |
| Principal investigator 1 | AstraZeneca UK Limited | $312,899.41 | 02/06/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | Phase I Single Dose,Non Randomised,Ope NLabel,Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics,Safety and Tolerability of Mitiperstat | No dispute reported | 06/30/2026 | 1185547135 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,996.22 | 02/05/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546483 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $7,092.70 | 02/05/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,662.65 | 02/05/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184152432 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 02/03/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781468 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781370 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781372 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781374 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781378 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.95 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $85.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781394 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781396 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781398 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781408 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781414 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781416 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781422 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781424 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781428 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781430 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781432 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781436 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781442 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781448 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781452 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781456 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,898.00 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781460 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781462 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/30/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781466 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $560,621.48 | 01/30/2025 | Non-covered Recipient Entity American Research Corporation | Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment | No dispute reported | 06/30/2026 | 1235999029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/29/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781412 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $14,817.53 | 01/29/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546473 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,465.85 | 01/29/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546479 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $561,877.38 | 01/28/2025 | Non-covered Recipient Entity American Research Corporation | Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment | No dispute reported | 06/30/2026 | 1235999031 |
| Principal investigator 1 | Gilead Sciences, Inc. | $7,398.94 | 01/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION, INC. | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229203750 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,442.92 | 01/28/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192166424 |
| Principal investigator 1 | Eli Lilly and Company | $1,214.24 | 01/27/2025 | Non-covered Recipient Entity THE TEXAS LIVER INSTITUTE | A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS | No dispute reported | 06/30/2026 | 1187891106 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781376 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781382 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781388 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781400 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781402 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781404 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781406 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781410 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781418 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781420 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781426 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781434 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781438 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781440 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781444 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781446 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.22 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781450 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.26 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781458 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $350.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220781464 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $648.00 | 01/23/2025 | Non-covered Recipient Entity Texas Liver Institute Ste 101 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial | No dispute reported | 06/30/2026 | 1220781478 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,788.46 | 01/23/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238594 |
| Principal investigator 1 | AstraZeneca UK Limited | $15,350.00 | 01/22/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | a Phase I Single Dose Non Randomised OpenL abel Parallel Group Study to Investigate the Effect of Hepatic Impairment on the pharmacokinetics Safety, and Tolerability of Balcinrenone | No dispute reported | 06/30/2026 | 1185547149 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $430,104.90 | 01/22/2025 | Non-covered Recipient Entity American Research Corporation | A Phase 1, Multicenter, Open-label, Single -dose Study to Assess the Pharmacokinetics of Repotrectinib in Healthy Participants and those with Moderate, and Severe Hepatic Impairment | No dispute reported | 06/30/2026 | 1235999033 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $34,370.85 | 01/22/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP | A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SA | No dispute reported | 06/30/2026 | 1192170021 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,491.00 | 01/22/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1184306801 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,039.55 | 01/21/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184149050 |
| Principal investigator 1 | Eli Lilly and Company | $34,643.03 | 01/17/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORP INC | A PHASE 1, MULTICENTER, PARALLEL, SINGLE-DOSE, OPEN-LABEL, SINGLE-PERIOD STUDY OF LY3502970 IN PARTICIPANTS WITH NORMAL HEPATIC FUNCTION AND PARTICIPANTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1187876251 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,070.90 | 01/17/2025 | Non-covered Recipient Entity American Research Corporation | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176546463 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $742.50 | 01/17/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546465 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $540.00 | 01/17/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546467 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $297.00 | 01/17/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546469 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $337.50 | 01/17/2025 | Non-covered Recipient Entity American Research Corporation | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176546471 |
| Principal investigator 1 | AstraZeneca UK Limited | $39,922.75 | 01/13/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Phase I Single-Dose Non-Randomised Open-Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD0780 | No dispute reported | 06/30/2026 | 1185547153 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $3,618.00 | 01/09/2025 | Non-covered Recipient Entity TEXAS LIVER INSTITUTE | A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS | No dispute reported | 06/30/2026 | 1235969821 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,414.65 | 01/09/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192166808 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,716.24 | 01/09/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,743.35 | 01/07/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184145782 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,217.78 | 01/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A Multicentre Randomised Double-blind Placebo-Controlled Phase 2b Study to Evaluate the Safety of ZibotentanDapagliflozin in Combination Compared to Zibotentan Monotherapy as well as ZibotentanDapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants with Cirrhosis | No dispute reported | 06/30/2026 | 1185547137 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,021.80 | 01/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248237903 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $825.00 | 01/03/2025 | Non-covered Recipient Entity AMERICAN RESEARCH CORPORATION | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248237915 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $249,905.29 | 01/02/2025 | Non-covered Recipient Entity TEXAS LIVER INSTITUTE | A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS | No dispute reported | 06/30/2026 | 1235969775 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $5,483.20 | 01/02/2025 | Non-covered Recipient Entity TEXAS LIVER INSTITUTE | A PHASE 1, OPEN-LABEL STUDY OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE-DOSE VIMSELTINIB IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL PARTICIPANTS | No dispute reported | 06/30/2026 | 1235969779 |